bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events
Item 8.01Other Events
On February 3, 2017, bluebird bio, Inc. issued a press release
announcing the treatment of the first patient under the amended
study protocol for its HGB-206 study, a Phase I clinical study of
its LentiGlobin product candidate in patients with severe sickle
cell disease. The full text of the press release regarding the
announcement is filed as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
|
99.1 |
Press release issued by bluebird bio, Inc. on February 3, |
|
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline. bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information
bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session 00.00 at 76.70 with 595,541 shares trading hands.